Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients

T. Gamucci, L. Moscetti, L. Mentuccia, L. Pizzuti, M. Mauri, G. Zampa, I. Pavese, I. Sperduti, A. Vaccaro, P. Vici

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Diarrhea in relation to the lapatinib-capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modified schedule in its administration, aimed primarily to evaluate grade (G) ≥2 diarrhea incidence and, secondarily, treatment efficacy. Patients and methods: Treatment schedule consisted of lapatinib 1,250 mg daily for the first 10 days, then in combination with capecitabine, 2,000 mg/m2, starting day 11 for the first cycle, and thereafter from day 8, for 14 days of a 21-day cycle, in 3 daily administrations. Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day. Results: Among 38 patients treated and analyzed, the incidence of G ≥ 2 diarrhea was 13.2 %. In 28 patients diarrhea was not observed, while G1-2 diarrhea was reported in 9 (23.7 %) patients; a single episode of G3 diarrhea was observed in 1 (2.6 %) patient. Overall response rate was 34.2 %, clinical benefit 55.3 %, and median progression-free survival 10 months. Conclusion: The results of the present post hoc analysis are very encouraging, both in terms of tolerability and treatment efficacy, and all data compare favorably with previous reports of "conventional" administration of the lapatinib-capecitabine regimen.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalJournal of Cancer Research and Clinical Oncology
Volume140
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Diarrhea
Appointments and Schedules
Breast Neoplasms
Cholestyramine Resin
Incidence
Disease-Free Survival
Capecitabine
lapatinib
Water
Therapeutics

Keywords

  • Advanced breast cancer
  • Capecitabine
  • Diarrhea
  • HER2-positive
  • Lapatinib
  • Schedule modification

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. / Gamucci, T.; Moscetti, L.; Mentuccia, L.; Pizzuti, L.; Mauri, M.; Zampa, G.; Pavese, I.; Sperduti, I.; Vaccaro, A.; Vici, P.

In: Journal of Cancer Research and Clinical Oncology, Vol. 140, No. 2, 02.2014, p. 221-226.

Research output: Contribution to journalArticle

Gamucci, T, Moscetti, L, Mentuccia, L, Pizzuti, L, Mauri, M, Zampa, G, Pavese, I, Sperduti, I, Vaccaro, A & Vici, P 2014, 'Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients', Journal of Cancer Research and Clinical Oncology, vol. 140, no. 2, pp. 221-226. https://doi.org/10.1007/s00432-013-1556-4
Gamucci, T. ; Moscetti, L. ; Mentuccia, L. ; Pizzuti, L. ; Mauri, M. ; Zampa, G. ; Pavese, I. ; Sperduti, I. ; Vaccaro, A. ; Vici, P. / Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. In: Journal of Cancer Research and Clinical Oncology. 2014 ; Vol. 140, No. 2. pp. 221-226.
@article{cf78d2742dce40ba8d2fdf64880d90c6,
title = "Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients",
abstract = "Purpose: Diarrhea in relation to the lapatinib-capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modified schedule in its administration, aimed primarily to evaluate grade (G) ≥2 diarrhea incidence and, secondarily, treatment efficacy. Patients and methods: Treatment schedule consisted of lapatinib 1,250 mg daily for the first 10 days, then in combination with capecitabine, 2,000 mg/m2, starting day 11 for the first cycle, and thereafter from day 8, for 14 days of a 21-day cycle, in 3 daily administrations. Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day. Results: Among 38 patients treated and analyzed, the incidence of G ≥ 2 diarrhea was 13.2 {\%}. In 28 patients diarrhea was not observed, while G1-2 diarrhea was reported in 9 (23.7 {\%}) patients; a single episode of G3 diarrhea was observed in 1 (2.6 {\%}) patient. Overall response rate was 34.2 {\%}, clinical benefit 55.3 {\%}, and median progression-free survival 10 months. Conclusion: The results of the present post hoc analysis are very encouraging, both in terms of tolerability and treatment efficacy, and all data compare favorably with previous reports of {"}conventional{"} administration of the lapatinib-capecitabine regimen.",
keywords = "Advanced breast cancer, Capecitabine, Diarrhea, HER2-positive, Lapatinib, Schedule modification",
author = "T. Gamucci and L. Moscetti and L. Mentuccia and L. Pizzuti and M. Mauri and G. Zampa and I. Pavese and I. Sperduti and A. Vaccaro and P. Vici",
year = "2014",
month = "2",
doi = "10.1007/s00432-013-1556-4",
language = "English",
volume = "140",
pages = "221--226",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients

AU - Gamucci, T.

AU - Moscetti, L.

AU - Mentuccia, L.

AU - Pizzuti, L.

AU - Mauri, M.

AU - Zampa, G.

AU - Pavese, I.

AU - Sperduti, I.

AU - Vaccaro, A.

AU - Vici, P.

PY - 2014/2

Y1 - 2014/2

N2 - Purpose: Diarrhea in relation to the lapatinib-capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modified schedule in its administration, aimed primarily to evaluate grade (G) ≥2 diarrhea incidence and, secondarily, treatment efficacy. Patients and methods: Treatment schedule consisted of lapatinib 1,250 mg daily for the first 10 days, then in combination with capecitabine, 2,000 mg/m2, starting day 11 for the first cycle, and thereafter from day 8, for 14 days of a 21-day cycle, in 3 daily administrations. Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day. Results: Among 38 patients treated and analyzed, the incidence of G ≥ 2 diarrhea was 13.2 %. In 28 patients diarrhea was not observed, while G1-2 diarrhea was reported in 9 (23.7 %) patients; a single episode of G3 diarrhea was observed in 1 (2.6 %) patient. Overall response rate was 34.2 %, clinical benefit 55.3 %, and median progression-free survival 10 months. Conclusion: The results of the present post hoc analysis are very encouraging, both in terms of tolerability and treatment efficacy, and all data compare favorably with previous reports of "conventional" administration of the lapatinib-capecitabine regimen.

AB - Purpose: Diarrhea in relation to the lapatinib-capecitabine regimen is a common and debilitating side effect which may interfere with optimal treatment delivery. We performed a post hoc analysis in human epidermal growth factor receptor 2-positive advanced breast cancer patients treated with a modified schedule in its administration, aimed primarily to evaluate grade (G) ≥2 diarrhea incidence and, secondarily, treatment efficacy. Patients and methods: Treatment schedule consisted of lapatinib 1,250 mg daily for the first 10 days, then in combination with capecitabine, 2,000 mg/m2, starting day 11 for the first cycle, and thereafter from day 8, for 14 days of a 21-day cycle, in 3 daily administrations. Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day. Results: Among 38 patients treated and analyzed, the incidence of G ≥ 2 diarrhea was 13.2 %. In 28 patients diarrhea was not observed, while G1-2 diarrhea was reported in 9 (23.7 %) patients; a single episode of G3 diarrhea was observed in 1 (2.6 %) patient. Overall response rate was 34.2 %, clinical benefit 55.3 %, and median progression-free survival 10 months. Conclusion: The results of the present post hoc analysis are very encouraging, both in terms of tolerability and treatment efficacy, and all data compare favorably with previous reports of "conventional" administration of the lapatinib-capecitabine regimen.

KW - Advanced breast cancer

KW - Capecitabine

KW - Diarrhea

KW - HER2-positive

KW - Lapatinib

KW - Schedule modification

UR - http://www.scopus.com/inward/record.url?scp=84895074975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895074975&partnerID=8YFLogxK

U2 - 10.1007/s00432-013-1556-4

DO - 10.1007/s00432-013-1556-4

M3 - Article

C2 - 24292401

AN - SCOPUS:84895074975

VL - 140

SP - 221

EP - 226

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 2

ER -